Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants by Schweren, Lizanne J. S. et al.
 
 
 University of Groningen
Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder
and the Effects of Stimulants
Schweren, Lizanne J. S.; Hartman, Catharina A.; Heslenfeld, Dirk J.; van der Meer, Dennis;
Franke, Barbara; Oosterlaan, Jaap; Buitelaar, Jan K.; Faraone, Stephen V.; Hoekstra, Pieter
J.
Published in:
Journal of the American Academy of Child and Adolescent Psychiatry
DOI:
10.1016/j.jaac.2015.05.014
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Schweren, L. J. S., Hartman, C. A., Heslenfeld, D. J., van der Meer, D., Franke, B., Oosterlaan, J.,
Buitelaar, J. K., Faraone, S. V., & Hoekstra, P. J. (2015). Thinner Medial Temporal Cortex in Adolescents
With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants. Journal of the American
Academy of Child and Adolescent Psychiatry, 54(8), 660-667. https://doi.org/10.1016/j.jaac.2015.05.014
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Accepted Manuscript
Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity
Disorder and the Effects of Stimulants
Lizanne J.S. Schweren, MSc, Catharina A. Hartman, PhD, Dirk J. Heslenfeld, PhD,
Dennis van der Meer, MSc, Barbara Franke, PhD, Jaap Oosterlaan, PhD, Jan K.




To appear in: Journal of the American Academy of Child & Adolescent
Psychiatry
Received Date: 27 November 2014
Revised Date: 28 May 2015
Accepted Date: 29 May 2015
Please cite this article as: Schweren LJS, Hartman CA, Heslenfeld DJ, van der Meer D, Franke B,
Oosterlaan J, Buitelaar JK, Faraone SV, Hoekstra PJ, Thinner Medial Temporal Cortex in Adolescents
With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants, Journal of the American
Academy of Child & Adolescent Psychiatry (2015), doi: 10.1016/j.jaac.2015.05.014.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all













Page 1 of 2 
 
Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of 
Stimulants  
RH = Cortical Thickness in Adolescent ADHD 
Lizanne J.S. Schweren, MSc; Catharina A. Hartman, PhD; Dirk J. Heslenfeld, PhD; Dennis van der Meer, MSc; 
Barbara Franke, PhD; Jaap Oosterlaan, PhD; Jan K. Buitelaar, MD, PhD; Stephen V. Faraone, PhD; Pieter J. 
Hoekstra, MD, PhD 
This article is discussed in an editorial by Dr. Philip Shaw on page xx. 
Supplemental material cited in this article is available online. 
Accepted June 2, 2015 
This article was reviewed under and accepted by ad hoc editor Daniel S. Pine, MD. 
Ms. Schweren, Drs. Hartman and Hoekstra, and Mr. van der Meer are with University of Groningen, University 
Medical Center Groningen, Groningen, The Netherlands. Drs. Heslenfeld and Oosterlaan are with VU University 
Amsterdam, The Netherlands. Drs. Franke and Buitelaar are with Radboud University Medical Center, Donders 
Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Dr. Buitelaar is also with Karakter Child 
and Adolescent Psychiatry University Centre Nijmegen. Dr. Faraone is with State University of New York Upstate 
Medical University, Syracuse, New York. 
This work was supported by National Institutes of Health Grant R01MH62873, Netherlands Organization for 
Scientific Research (NOW) Large Investment Grant 1750102007010, ZonMW Priority Medicines for Children 
Grant 113202005, as well as grants from Radboud University Nijmegen Medical Center, University Medical Center 
Groningen and Accare, and VU University Amsterdam. 
Dr. Hartman served as the statistical expert for this research. 
Disclosure: Dr. Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for 
Janssen Cilag BV, Eli Lilly and Co., Shire, Novartis, Lundbeck, and Servier. He is not an employee of any of these 
companies, or a stock shareholder of any of these companies. He has no other financial or material support, 
including expert testimony, patents, or royalties. Dr. Faraone has received consulting income, travel expenses, 
and/or research support from, and/or has served one the advisory board for Pfizer, Ironshore, Shire, Akili Interactive 
Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences, and research support from the 













Page 2 of 2 
 
sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he has received consulting fees 
or served on advisory boards or participated in continuing medical education programs sponsored by Shire, Alcobra, 
Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly and Co. He has received royalties from books published by 
Guilford Press (Straight Talk about Your Child’s Mental Health), Oxford University Press (Schizophrenia: The 
Facts), and Elsevier (ADHD: Non-Pharmacologic Treatments). Dr. Hoekstra has been a paid consultant to Shire and 
Eli Lilly and Co. Drs. Hartman, Heslenfeld, Franke, Oosterlaan, Ms. Schweren, and Mr. van der Meer report no 
biomedical financial interests or potential conflicts of interest. 
Correspondence to Lizanne Schweren, MSc, University Medical Center Groningen, Department of Psychiatry, 



















Objective: Attention-deficit/hyperactivity disorder (ADHD) has been associated with widespread changes in 
cortical thickness (CT). Findings have been inconsistent, however, possibly due to age differences between samples. 
Cortical changes have also been suggested to be reduced or disappear with stimulant treatment. We investigated 
differences in CT between adolescents/young adults with and without ADHD in the largest ADHD sample to date, 
the NeuroIMAGE sample. Second, we investigated how such differences were related to age and stimulant 
treatment.   
Method: Participants (ADHD=306; healthy controls=184, 61% male, 8-28 years old, mean age=17) underwent 
structural magnetic resonance imaging. Participants and pharmacies provided detailed information regarding 
lifetime stimulant treatment, including cumulative intake and age of treatment initiation and cessation. Vertex-wise 
statistics were performed in Freesurfer, modeling the main effect of diagnosis on CT and its interaction with age. 
Effects of stimulant treatment parameters on CT were modeled within the sample with ADHD.  
Results: After correction for multiple comparisons, participants with ADHD showed decreased medial temporal CT 
in both left (pCLUSTER=.008) and right (pCLUSTER=.038) hemispheres. These differences were present across different 
ages and were associated with symptoms of hyperactivity and prosocial behavior. There were no age-by-diagnosis 
interaction effects. None of the treatment parameters predicted CT within ADHD.  
Conclusion: Individuals with ADHD showed thinner bilateral medial temporal cortex throughout adolescence and 
young adulthood compared to healthy controls. We found no association between CT and stimulant treatment. The 
cross-sectional design of the current study warrants cautious interpretation of the findings. 


















Magnetic resonance imaging (MRI) has revealed structural and functional brain changes associated with 
attention-deficit/hyperactivity disorder (ADHD)1–3. Surface-based reconstruction of the cortical sheet allows 
quantification of different features of cortical structure, including volume, thickness, surface area, and curvature. 
Such features may represent distinct developmental processes having separate developmental trajectories4. Changes 
in different features may be associated with distinct forms of psychopathology5. Volumetric studies have 
consistently reported global cortical volume reduction in individuals with ADHD2,6. Widespread reductions of 
cortical thickness (CT) have also been implicated in ADHD. Children and adults with ADHD have shown decreased 
CT in frontal cortex7–12, inferior and superior parietal cortex10–12, temporal pole, and medial temporal cortex11,13. 
However, patterns of ADHD-related cortical changes differ widely across studies. There have been multiple reports 
of increased rather than decreased CT in individuals with ADHD14,15, and other studies have found no association 
between CT and clinical features of ADHD8,12.  
Discrepant patterns of CT changes in ADHD between studies may result from age differences in groups 
under study. ADHD often persists into adulthood16, typically showing reduced hyperactivity but persistent 
inattention throughout adolescence. In typical development, CT increases during childhood to reach its peak in early 
adolescence, after which it decreases again. The “maturational delay” hypothesis of ADHD proposes that CT 
changes observed in children with ADHD reflect the ADHD group lagging behind the typically developing group 
and reaching peak CT at a later age17. As they grow older, adolescents with ADHD are proposed to “catch up” with 
their unaffected peers, resulting in fewer or no cortical changes along with a decline in clinical symptoms at later 
age (remission). The hypothesis is supported by an impressive longitudinal sample of children and adolescents, with 
an average age of twelve17. A substantial proportion of children with ADHD, however, continues to have symptoms 
in late adolescence and adulthood18. Differences in CT in adults with ADHD have also been reported14,15, suggesting 
that individuals with persistent ADHD do not show cortical normalization during late adolescence. Unfortunately, 
the majority of studies focused on either children or adults, and the development of CT in (late) adolescent ADHD 
has not extensively been documented. One cross-sectional study found both increases and decreases in CT in older 
adolescents/young adults with ADHD14. Zooming in on the late adolescent phase could aid in further elaboration of 















A substantial proportion of individuals with ADHD are prescribed stimulants. MRI studies investigating 
the effect of methylphenidate treatment on brain volume and function in children with ADHD have suggested at 
least partially normalizing effects1,2,19,20. Very few have studied the effect of stimulants on CT. In a longitudinal 
study, Shaw et al.21 showed normalized developmental trajectories of CT in stimulant-treated but not in non-treated 
children with ADHD. Treatment effects were local rather than global, affecting CT in the left dorsolateral prefrontal 
cortex, and right motor and posterior parietal cortex. By contrast, other studies have reported greater CT 
abnormalities in previously medicated patients12 or observed no differences between stimulant-naïve and stimulant-
treated patients10.  
The investigation of long-term treatment effects in pediatric groups is complex. Long-term effects 
(spanning multiple years) may only be assessed in observational studies in which individuals with ADHD have not 
been randomized over stimulant and non-stimulant treatment. This creates the possibility of confound by indication, 
i.e. non-stimulant-treated cases may be less severe or may differ from stimulant-treated cases in other ways. An 
advantage of observational studies, however, is that study samples are typically representative of the study 
population. To investigate stimulant treatment effects on brain structure, “treated” and “untreated” individuals with 
ADHD are typically compared. However, this distinction is rather crude and neglects between-subject variation in 
treatment history. Whereas some classify past users as “treated”21, others may classify them as “untreated”22 or 
exclude such participants23. Investigating treatment heterogeneity in more detail may reveal mechanisms by which 
stimulant treatment may affect brain structure.  
In the current study, we compared CT in a large sample of adolescents/young adults with ADHD (n=306) 
to that of a healthy control sample (n=184). Further, the linear and non-linear effects of age on changes in CT 
associated with ADHD (if any) were investigated. Last, we tested the effect of multiple well-defined stimulant 
treatment parameters. The current study adds to the previous volumetric findings of our group with ADHD being 
associated with global rather than local volume reductions6. Other neuroimaging studies based on the same sample 
investigated volumetric features,24–26 structural connectivity,27–29 or functional MRI.30–33 To the best of our 



















Participants were selected from the Dutch follow-up phase of the International Multicenter ADHD Genetics 
(IMAGE) study34–36. ADHD diagnosis, ADHD severity, and presence of comorbid disorders were established using 
an algorithm based on both the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-
SADS37) and Conners’ ADHD questionnaires for parents38, teachers39, and adult participants40. See 41 and 
Supplement 1 (available online) for more details and relevant publications regarding the sample and diagnostic 
algorithm. IQ was estimated from the subtests “vocabulary” and “block design” of the Wechsler Intelligence Scale 
for Children – Version III42 (participants ≤ 16 years old) or the Wechsler Adult Intelligence Scale – Version III43 
(participants > 16 years old). The subtest “digit span” was administered as an indication of working memory 
capacity. In addition, the Strengths and Difficulties Questionnaire for Children (CSDQ) was administered.44 
Socioeconomic status (SES) was calculated as the average (of both parents) number of years of education. 
Participants withheld use of psychoactive drugs for 48 hours prior to their visit. Informed consent was signed by all 
participants and parents (parents signed informed consent for participants < 12 years old). Testing took place at the 
University Medical Center of either Amsterdam or Nijmegen. The study was approved by the local ethical 
committee. The final sample consisted of 306 participants with ADHD and 184 healthy control participants between 
the ages of 8.3 and 27.8 years old (M=17.05, SD=3.33).  
Assessment of medication history 
Lifetime medication transcripts from pharmacies were available for 74% and covered lifespan for 25% of 
participants with ADHD. In addition, a questionnaire was administered to all participants and parents assessing 
lifetime history of psychoactive medication. When pharmacy transcripts did not fully cover the self-reported 
treatment period, medication parameters of the missing period(s) were calculated from the questionnaire data and 
were added to the measures derived from the pharmacy. Retrospective assessment of ADHD medication has shown 
good to excellent concordance between parent- and physician-report, even after multiple years.45 The following 
indices of stimulant treatment (methylphenidate immediate/extended release and dexamphetamine preparations) 
were calculated: history of treatment (stimulant-exposed vs. stimulant-naïve); start age; stop age; median age of 
exposure (age in years at the median of all exposed days); treatment duration corrected for age (treatment duration 
divided by [age minus the minimum start-age within the sample, i.e. age 2.3]); mean daily dose (average dose in mg 















treatment duration multiplied by mean daily dose); and time since last treatment (age minus stop age). For stimulant-
naïve patients, mean daily dose, treatment duration, and cumulative intake were zero; start age was imputed as the 
participant’s age at scan (mimicking late initiation), and stop age was imputed as age 2.3 (mimicking early 
cessation). 
MRI acquisition and analysis 
MRI data was acquired at 1.5T on a Siemens Sonata scanner at the University Medical Center in 
Amsterdam, and on a Siemens Avanto scanner in Nijmegen, with an identical 8-channel phased array coil and 
identical acquisition parameters. There were no major hardware upgrades on either of the scanners during the study. 
Comparability of  MRI data from the two sites has extensively been described elsewhere41. Scanning parameters and 
quality assurance procedures are described in Supplement 1, available online. Cortical reconstruction was performed 
with Freesurfer (http://surfer.nmr.mgh.harvard.edu/)46–48. Freesurfer is an automated technique to create a 3D 
reconstruction of the cortical sheet that uses both intensity and continuity information, with good test-retest 
reliability across scanner stations49. CT was calculated for each vertex on the reconstructed cortical sheet and 
defined as the closest distance from the gray/white boundary to the gray/CSF boundary50. Cortical surface area, used 
in post hoc analyses, was measured at the geometric middle between the inner and outer cortical surfaces. A 10mm 
full width at half maximum surface-based smoothing kernel was applied. Average CT per participant was calculated 
across all vertices. Total brain volume was calculated as the sum of Freesurfer estimated total grey and white matter 
volume.  
Data analysis  
Statistical modeling was performed with the glmfit-tool embedded in Freesurfer, and in the second instance 
in SPSS version 20.0.0.251. The effects of diagnostic group (healthy controls vs. participants with ADHD) and 
stimulant exposure (stimulant-exposed vs. stimulant-naïve) on CT were analyzed in a linear main effects model 
including gender, scanner location, and SES as covariates, and age and age2 as optional per-vertex covariates. 
Optimal modeling of age as a covariate across the cortex was obtained in a two-step approach: First, between-group 
differences were evaluated with both age and age2 in the model in all vertices where age2 significantly contributed to 
the prediction of CT. Second, in all other vertices, age was kept in the model only where it significantly contributed 
to the prediction of CT. As a result, each vertex contained either a quadratic, a linear, or no effect of age (Figure S2, 















the ADHD phenotype52. In two additional vertex-wise models, we tested age-by-diagnosis and age2-by-diagnosis 
interactions.  
Comparing stimulant-exposed to stimulant-naïve participants allowed detection of between-group 
differences of medium effect size (nEXPOSED=270, nNAÏVE=36; two-tailed alpha=0.05, power=0.80, smallest detectable 
Cohen’s d effect size=0.50). We further investigated treatment effects by vertex-wise linear modeling of continuous 
treatment variables within the ADHD sample, i.e. treatment duration corrected for age, mean daily dose, cumulative 
intake corrected for age, start age, stop age, median age of exposure, and time since last treatment. These parameters 
were initially tested in seven separate models, predicting CT with gender, scanner location, SES, age, and age2 as 
covariates (Bonferroni correction, cluster-wise alpha/7), and then simultaneously for those treatment parameters 
significantly predicting CT. Unlike in the case-control analyses, linear and quadratic age-terms were included for 
each vertex, as they were expected to be correlated with the predictor variables. With this approach, regression 
coefficients of small to medium effect size could be detected (nTOTAL=290; per vertex: two-tailed alpha=0.007, 
power=0.80, smallest detectable Cohen’s ƒ2 effect size =0.067). 
We applied Monte Carlo simulation testing (10.000 iterations, vertex-wise threshold p<.01, cluster-wise 
threshold p<.05) to correct for multiple comparisons. Within each significant cluster, mean CT and surface area 
were extracted for each participant in standard space to perform post hoc and sensitivity analyses in SPSS. We 
reported cluster size and p value from the Monte Carlo simulation testing in Freesurfer, and estimated marginal 
mean CT per group and Cohen’s d effect size from the SPSS analyses.  
Exploratory post hoc analyses were performed to investigate clinical correlates of case-control differences 
or treatment effects within participants with ADHD (n=306). In separate linear mixed effects models, mean CT 
within each cluster was predicted by number of hyperactivity symptoms, number of inattention symptoms (both 
derived from the K-SADS interview and Conners’ questionnaires), four subscales of the CSDQ (conduct problems, 
emotional problems, peer problems, and prosocial behavior), working memory capacity (maximum digit span 
backwards), and IQ. Gender, scanner site, SES, and, if appropriate, age and age2, were used as covariates. Second, 
we tested whether cortical surface area was affected in clusters of significant between-group or treatment effects. 
















Sensitivity analyses were performed to investigate the robustness of our findings. First, a random intercept 
per family was added to the model to account for dependencies among participants from the same family. Further 
sensitivity analyses entailed repeating each analysis with IQ, average CT, and total brain volume as additional 
covariates, respectively, and repeating each analysis within subgroups, i.e. within each of the two scanning sites, 
within boys and girls, within five age quintiles (age<14.05; age=14.06-16.21; age=16.22-18.01; age=18.02-20.04; 
and age>20.04), within participants who had never received psychoactive treatment other than stimulants, and 
within participants without any comorbid diagnoses (Table S3, available online). Furthermore, vertex-wise analyses 
in Freesurfer were repeated with IQ, average CT, and total brain volume as covariates to allow detection of 
additional clusters (Table S4 and Figure S4, available online). 
 
RESULTS 
Demographic and clinical information 
Compared to healthy controls, participants with ADHD were more likely to be male, to have participated in 
Nijmegen, and had lower SES and IQ (Table 1). Forty-four percent of participants with ADHD were of combined 
type (n=134). Thirty-three percent of participants with ADHD had a comorbid disorder (n=100), mostly oppositional 
defiant disorder and/or conduct disorder (n=91, 29.7%), but also tic disorders (n=3, 1.0%) and anxiety/depression 
(n=11, 3.6%). Eighty-eight percent (n=254) of participants with ADHD had received stimulant treatment at some 
point in their lives, including immediate-release (n=245, 84.5%) and/or extended-release (n=201, 69.3%) 
methylphenidate preparations and/or dexamphetamine (n=25, 8.6%). Compared to stimulant-naïve participants, 
stimulant-exposed participants were more likely to be male, to have participated in Nijmegen, were younger, and 
had lower IQ and more hyperactivity-impulsivity symptoms (Table 2).  
Medication parameters could be calculated for the majority of participants with ADHD (n=290, 94.5%; 
including 254 stimulant-exposed participants, 87.6%). On average stimulant-exposed participants had received 4.9 
years of stimulant treatment (SD=3.19; range 0.05-14.17) corresponding to 33% of their lives. They started 
stimulant treatment, on average, at age 8.5 (SD=2.75; range 2.30-20.61), and received a mean dose of 34 mg per day 
(SD=12.47; range 10.00-78.52). Forty-nine percent (n=125) of stimulant-exposed participants had ceased treatment 
at least three months and on average 1.6 years prior to study participation, with an average stop age of 15.5 years 















other than stimulants, including atomoxetine (n=39, 13.5%), clonidine (n=18, 6.2%), antidepressants (n=16, 5.5%), 
atypical antipsychotics (n=48, 16.6%), and benzodiazepines/anxiolytics (n=15, 5.2%).  
 
CT in participants with ADHD vs healthy controls  
Participants with ADHD showed decreased CT in the medial temporal cortex in both left (cluster 
size=468mm2; pCLUSTER=.008; Cohen’s d effect size=0.443; CTHC=3.323mm; CTADHD=3.182mm) and right 
hemisphere (cluster size=368mm2; pCLUSTER=.038; Cohen’s d effect size=0.445; CTHC=3.224mm; 
CTADHD=3.113mm; Figure 1). These case-control differences were significant after accounting for dependencies 
among participants from the same family, were present in both testing sites and both genders, remained significant 
when participants with comorbid diagnoses or psychoactive medication other than stimulants were excluded, and 
when IQ, total brain volume, and average CT (respectively) were added to the model as additional covariates (Table 
S3, available online). In vertex-wise analyses with IQ and average CT as an additional covariate, a left superior 
parietal cluster of increased CT in participants with ADHD reached significance as well (Table S4, and Figure S4, 
available online). In the primary analyses, the same pattern was observed but failed to reach significance after 
correction for multiple testing (data not shown). 
Age2 did not contribute to the prediction of CT in either of the medial temporal clusters, and the linear age 
term contributed in the right but not the left hemisphere cluster (Figure S2, available online). CT of the ADHD and 
healthy control groups within each cluster was plotted in five age quintiles (Figure 2). The direction of effect 
remained unchanged in all age groups, and there were no age-by-diagnosis (pLEFT=.137, pRIGHT=.328) or age-
quintile-by-diagnosis (pLEFT=.085, pRIGHT=.135) interaction effects. In accordance, we found no age/age
2-by-
diagnosis interaction effects in vertex-wise analyses. There was no between-group difference in cortical surface area 
within the left (p=.241) or right (p=.166) cluster. Main effects of gender, site, and SES are in Table S2, available 
online. 
Stimulant exposure 
There were no differences in CT between stimulant-treated and stimulant-naïve participants with ADHD. 
Treatment duration corrected for age, mean daily dose, cumulative intake corrected for age, start age, stop age, 
median age of exposure, and time since last treatment did not predict CT within the ADHD sample. 















Exploratory post-hoc analyses indicated that in participants with ADHD, CT within the left medial 
temporal cluster was related to number of hyperactivity symptoms (β=-0.039; p=.020), but not to number of 
inattention symptoms (p=.571), conduct problems (p=.183), emotional problems (p=.200), peer problems (p=0.562), 
prosocial behavior (p=.647), working memory capacity (p=.651), or IQ (p=.730). Within the right medial temporal 
cluster, CT was related to prosocial behavior (β=0.031; p=.034), but not to symptoms of inattention (p=.985), 
hyperactivity (p=.246), conduct problems (p=.979), emotional problems (p=.971), peer problems (p=.768), working 
memory capacity (p=.789), or IQ (p=.817).  
 
DISCUSSION 
The current study investigated CT among adolescents and young adults with ADHD and its associations 
with age and stimulant treatment. We found bilateral decreased medial temporal CT in participants with ADHD 
compared to healthy control participants. These differences were present across different ages, were not 
accompanied by changes in cortical surface area, were not driven by global brain changes, and were associated with 
symptoms of hyperactivity and prosocial behavior. Despite having the largest ADHD sample to date with substantial 
within-subject treatment variability, we found no association between CT and stimulant treatment history. 
Reduced CT in medial temporal regions, including the hippocampus, amygdala, and parahippocampal 
cortex, has previously been reported in pediatric12,53,54 and adult11 ADHD groups. Smaller medial temporal volumes 
have been associated with impaired response inhibition in individuals with ADHD55, and structural changes of the 
hippocampus and amygdala have been associated with emotional dysregulation56,57. In a volumetric study of the 
current sample, a decrease in overall grey matter volume but no changes in hippocampal or amygdalar volumes were 
detected in participants with ADHD.6 Discrepant findings may be expected, however, since cortical volume is 
determined by cortical thickness as well as other parameters (i.e., surface area and gyrification). In addition, 
analyses of regional cortical volumes (including the hippocampus) in the volumetric study were corrected for global 
brain changes. Smaller hippocampal volumes may have been masked by the reduction in total brain volume in 
participants with ADHD6. In the current study, adding global brain measures did not change our findings, suggesting 
that decreased medial temporal CT may not be related to global changes. Our findings add to the growing body of 
evidence suggesting that regions outside the frontal-striatal circuits may be important in the pathophysiology of 















hyperactivity symptoms, a core feature of ADHD. The clinical relevance of decreased medial temporal CT is to be 
further elaborated in future studies, in which hyperactivity and prosocial behavior but also typical medial temporal 
functions such as memory should be addressed.  
The current study being cross-sectional, any findings regarding developmental changes or age effects 
should be interpreted with caution. Nevertheless, our study provides several interesting findings regarding age and 
ADHD. First, both clusters of case-control difference occurred (at least partially) in regions where CT was not 
related to age (Figure 2). In most other vertices, CT decreases with increasing age (Figure S2, available online). 
Case-control differences thus occur in the absence of developmental changes in CT. Second, we found no age-by-
diagnosis or age2-by-diagnosis interaction effects. Thus, the medial temporal case-control differences are equally 
driven by younger and older participants. The developmental delay hypothesis proposes that, later in development, 
some children with ADHD “catch up” with their typically developing peers17, resulting in smaller cortical 
abnormalities accompanied by (at least partial) clinical remission. This hypothesis could not be tested in the current 
study, since no cases of remittent ADHD were included. We emphasize again the cross-sectional nature of the 
current study. As a group, the older participants with ADHD may differ from the younger ones. A sizeable portion 
of participants within the younger ADHD groups may remit during adolescence, whereas this has not occurred in the 
older ADHD groups. This more heterogeneous composition of the younger age groups may have masked any age-
by-diagnosis interaction effects. There is a clear need for long-term longitudinal studies to characterize cortical 
development associated with persistence and remission of ADHD during late adolescence/young adulthood. 
Despite having sufficient power to detect even small effects, we found no associations between stimulant 
treatment and CT. Any treatment parameter, regardless of its correlations with the other parameters, would have 
shown its individual effect (if any) in our initial approach of modeling each parameter separately. The absence of 
stimulant treatment effects has two implications for our findings. First, it aids the interpretation of the case-control 
differences. As the ADHD sample consisted largely of stimulant-exposed participants with an average treatment 
duration of almost five years, any case-control differences we observed may have been the result of stimulant 
treatment rather than associated with the ADHD phenotype. Two recent studies both reported hippocampal volume 
reduction in adults with ADHD who had during childhood been treated with stimulants, but not in stimulant-naïve 
adults with ADHD23,56. The lack of association between stimulant treatment and CT within our ADHD group, 















Second, our findings do not support with the hypothesis of CT normalization with stimulant treatment. 
Most previous studies suggesting structural normalization with stimulant treatment reported cortical volume rather 
than thickness, of which two recent studies found evidence in meta-regression analyses1,2. In one study, development 
of CT over time was found to be normalized in participants with ADHD who received stimulant-treatment (n=24) 
compared to those who did not (n=19). These effects were confined to specific brain regions, including the left 
dorsolateral prefrontal cortex21.  In a larger study of the same group, however, no stimulant treatment effects were 
found9. We found no evidence of stimulant treatment being associated with CT. Possibly, long-term stimulant 
treatment affects cortical volume but not thickness. Long-term treatment effects across different cortical features are 
an interesting opportunity for future studies. 
The current study had several strengths. First, our sample comprised older adolescents and young adults, an 
age group that has received very little attention in previous studies. Second, as pediatric long-term treatment effects 
cannot be studied in randomized clinical trials, the current study took advantage of its observational nature. This 
resulted in a large and representative sample, allowing a detailed investigation of between-subject variation in 
treatment history. Third, access to pharmacy records allowed exact quantification of lifetime stimulant exposure. 
This extent of detail has rarely been accomplished in previous studies. Our study had limitations too. The study was 
cross-sectional. An optimal design to investigate long-term outcomes would be longitudinal and include a pre-
treatment measurement. In accordance, an optimal study design would include individuals with remitted ADHD as 
well. Second, few participants with ADHD were naïve to stimulants, and the average treatment duration of the 
ADHD sample was relatively long. Future studies of treatment effects would benefit from targeted inclusion of 
additional stimulant-naïve individuals. Third, the large sample size did not allow manual editing of the Freesurfer 
segmentations, which may have affected reconstruction of the cortical surface especially in the anterior temporal 
lobes. However, we expect such distortions, if any, to be small and randomly distributed across the participant 
groups.  
In conclusion, we found reduced CT in bilateral medial temporal cortex in youths with ADHD compared to 
healthy controls. There were no age-by-diagnosis interaction effects. These findings suggest ADHD-related changes 
in CT existing throughout adolescence and young adulthood, and add to our prior report of overall grey matter 















treatment. Our cross-sectional findings suggest the importance of medial temporal regions in adolescent ADHD, and 
highlight the need for longitudinal studies of ADHD extending into late adolescence and young adulthood.  
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Figure Captions 
Figure 1: Regions of significant decrease in cortical thickness (cluster-wise p value < .05, corrected for multiple 
comparisons using Monte Carlo simulation testing) in participants with attention-deficit/hyperactivity disorder 
(ADHD) compared to healthy controls, indicated in red and projected on the pial surface of a standard brain 
template (fsaverage). Note: There were no regions of increased cortical thickness in participants with ADHD. 
Figure 2: Cortical thickness (CT) in participants with attention-deficit/hyperactivity disorder (ADHD) and healthy 
controls (HC), stratified by age (Q1<14.05y; Q2=14.06-16.21y; Q3=16.22-18.01y; Q4=18.02-20.04y; Q5>20.04y) 
within the medial temporal clusters of case-control difference. Note: Age-quintile-by-diagnosis interaction effects 

















Table 1. Demographic and Clinical Information of Participants With and Without Attention-
Deficit/Hyperactivity Disorder (ADHD) 
 HC ADHD  
 n % n % p 
Participants 184 37.6 306 62.4  
Male 92 50.0 209 68.3 .001 
Amsterdam 116 63.0 135 44.1 .001 
 Mean SD Mean SD  
Age 16.77 3.15 17.23 3.43 .138 
IQ 106.16 13.75 97.05 15.24 .001 
SES  13.33 2.50 11.61 2.23 .001 


















Table 2. Characteristics of the Exposed and Unexposed Participants With Attention-Deficit/Hyperactivity 
Disorder  
 Exposed Unexposed  
 n % n % p 
Participants 270 88.2 36 11.8  
Male 192 71.1 17 47.2 .004 
Amsterdam 104 38.5 31 86.1 .001 
Combined type 122 45.2 12 33.3 .178 
Comorbid disorder 89 33.0 11 30.6 .772 
   ODD/CD 82 30.4 9 25.0 .508 
   Tic disorder 3 1.1 0 0.0 .525 
   Anxiety / Depression 9 3.3 2 5.6 .501 
 Mean SD Mean SD  
Age 17.04 3.23 18.61 4.45 .048 
IQ 96.42 14.84 101.75 17.43 .049 
Number of symptoms  13.36 2.93 11.55 3.13 .001 
   Inattentive  7.34 1.71 6.75 1.59 .053 
   Hyperactive-impulsive 6.03 2.30 4.89 2.80 .024 
SES  11.60 2.25 11.69 2.12 .813 







































Supplement 1 – Method 
Description of the IMAGE-NeuroIMAGE Sample 
Three-hundred-thirty-one attention-deficit/hyperactivity (ADHD) families and 153 control families 
participated in a diagnostic interview, questionnaires, and extensive magnetic resonance imaging (MRI)  
scanning. The following inclusion criteria applied for all participants in the current study: participants had to be 
(1) between 8-30 years old at follow-up, (2) of European Caucasian descent, (3) have an IQ ≥ 70, (4) have no 
diagnosis of epilepsy, general learning difficulties, brain disorders, and known genetic disorders (such as Down 
syndrome), (5) have no contra indication to MR scanning, and (6) show no incidental findings on the MRI scan. 
Healthy control participants had to fulfill the following additional criteria: no current or past mental health care 
utilization, no sibling(s) with any past or current psychiatric diagnosis, and no current or past psychoactive 
medication use. As recruitment was family-based, multiple members of one family could be included in the same 
diagnostic group. Unaffected siblings of participants with ADHD were excluded. Previous relevant publications 
from our group regarding the same sample that are not in the reference list included a study focusing on working 
memory and another on the risk of developing substance use disorder in relation to stimulant treatment.1,2 
Scanning Parameters and Quality Control Procedures 
Structural MRI acquisition consisted of two T1-weighted 3D MP-RAGE scans (TI = 1,000 ms, TR = 
2,730 ms, TE = 2.95 ms, FA = 7°; parallel imaging by generalized autocalibrating partially parallel acquisition 
[GRAPPA]; 176 sagittal slices, voxel size 1 x 1 x 1 mm,  FOV = 256 x 256 x 176 mm). For each participant, the 
structural acquisition of highest quality was selected by visual inspection,3 accepting only scans with no/mild 
distortions. To assure Freesurfer reconstruction quality, the following reconstructions were subjected to visual 
inspection to detect regions of “flattened” or “spiky” surface and surface wholes: (1) twenty percent (randomly 
selected) of the sample; (2) all reconstructions based on a structural scan with mild distortions. Reconstructions 
that did not meet quality criteria were excluded from all analyses; no manual edits were made. 
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Supplement 2 – Covariates 
Figure S2. Clusters of significant main effects of the linear and quadratic age terms (light blue and dark blue, 
respectively; corrected for multiple comparisons using Monte Carlo simulation testing). Note: Increasing age 
was associated with decreasing cortical thickness. There were no regions of increasing cortical thickness with 


























Table S2. Gender, Scanner, and Socioeconomic Status (SES) 
Covariate Direction Hemi Region Size TMAX  PCLUSTER 
Gender Boys > Girls R Lingual cortex 522.67 -4.578 .00480 
  L Precentral cortex 374.89 -6.175 .03100 
  R Insula 439.79 -5.401 .01300 
  R Superior temporal cortex 475.71 -4.982 .00820 
  L Middle frontal cortex 353.99 -4.629 .04050 
 Girls > Boys R Posterior cingulate cortex 499.60 6.114 .00610 
  L Postcentral cortex 577.36 4.980 .00230 
  R Precentral cortex 360.60 3.398 .04190 
  R Inferior parietal cortex 410.96 5.105 .01930 
  R Medial orbitofrontal 458.62 6.134 .00960 
SES Neg R Lateral occipital cortex 434.31 -3.013 .01340 
Scanner site AMS < NIJM R Middle temporal cortex 1,196.71 -15.618 .00010 
  L Middle temporal cortex 3,396.30 -17.608 .00010 
  R Middle frontal cortex 7,402.56 -12.716 .00010 
  L Middle frontal cortex 9,300.90 -14.960 .00010 
 NIJM < AMS R Inferior parietal cortex 529.24 3.065 .00400 
  L Superior parietal cortex 8,971.47 7.844 .00010 
  R Middle frontal cortex 896.99 4.627 .00010 
  L Middle frontal cortex 2,012.35 6.515 .00010 
  R Precuneus cortex 3,257.91 8.543 .00010 
  R Supramarginal cortex 894.47 4.618 .00010 
Note: Clusters of significant main effects of covariates gender, scanner site, and SES (pvertex=.01, pcluster=.05, 
corrected for multiple testing), tested in the full model (cortical thickness is predicted by diagnostic status, 
scanner site, gender, SES, age, and age2). AMS = scanner in Amsterdam; L = left; NIJM = scanner in Nijmegen; 
Neg = negative correlation; PCLUSTER = cluster-wise p-value after correction for multiple comparisons; Pos = 















Supplement 3 – Sensitivity Analyses 
Table S3. Sensitivity Analyses  
  LH   RH   
 n EMMHC EMMADHD p EMMHC EMMADHD p 
Original analyses / all subjects  490 3.323 3.182 .001 3.224 3.113 .001 
Within Amsterdam 251  3.347 3.221 .003 3.207 3.136 .028 
Within Nijmegen 239  3.306 3.140 .001 3.256 3.092 .001 
Within boys 301 3.342 3.191 .001 3.222 3.110 .001 
Within girls 189 3.304 3.178 .014 3.238 3.113 .002 
Within age < 14.05 99 3.252 3.201 .526 3.198 3.092 .120 
Within age 14.05-16.21 98 3.347 3.242 .060 3.278 3.144 .007 
Within age 16.21-18.01 98 3.335 3.197 .037 3.211 3.142 .162 
Within age 18.01-20.04 97 3.416 3.119 .001 3.304 3.094 .001 
Within age > 20.04 98 3.336 3.173 .031 3.156 3.100 .334 
Excluding comedication 401 3.326 3.184 .001 3.221 3.117 .001 
Excluding comorbidity 389 3.326 3.193 .001 3.224 3.115 .001 
Additional covariate: IQ 490 3.321 3.184 .001 3.227 3.112 .001 
Additional covariate: TBV 490 3.323 3.183 .001 3.224 3.113 .001 
Additional covariate: average CT 490 3.318 3.185 .001 3.223 3.116 .001 
Note: Estimated marginal mean cortical thickness in subsamples of healthy control participants and participants 
with attention-deficit/hyperactivity disorder (ADHD), and associated p values within the left and right medial 
temporal cluster of significant case-control difference. CT = cortical thickness; EMM = estimated marginal mean 
cortical thickness in mm; HC = healthy control participants; LH = left hemisphere; p = cluster-wise p value after 


















Supplement 4 – Vertex-Wise Analyses With Additional Covariates (IQ, Total Brain Volume and Average 
Cortical Thickness) 
 
Table S4. Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Vs. Healthy Control (HC) 
Participants  
Additional covariate Region Cluster size pCLUSTER Cohen’s d EMMHC EMMADHD 
IQ L medial temporal  435.07 0.012 0.415 3.355 3.214 
 R medial temporal 357.37 0.043 0.436 3.235 3.117 
 L superior parietal 359.33 0.037 -0.434 2.091 2.204 
Average CT L medial temporal 440.36 0.006 0.417 3.334 3.199 
 R medial temporal 340.71 0.032 0.449 3.229 3.117 
 L superior parietal 385.43 0.014 -0.475 2.094 2.200 
TBV L medial temporal  475.00 0.009 0.425 3.349 3.207 
 R medial temporal 390.75 0.028 0.419 3.184 3.073 
Note: Regions of significant increased and decreased cortical thickness (CT; cluster-wise p value < .05, corrected 
for multiple comparisons using Monte Carlo simulation testing), in participants with ADHD compared to healthy 
control participants, in a statistical model including estimated IQ, total brain volume, or average cortical 
thickness as an additional covariate. EMM = estimated marginal mean cortical thickness in mm; L = left; 















Figure S4. Regions of significant decreased cortical thickness in red and increased cortical thickness in blue 
(cluster-wise p value < .05, corrected for multiple comparisons using Monte Carlo simulation testing), in 
participants with attention-deficit/hyperactivity disorder (ADHD) compared to healthy control participants, in a 
statistical model including estimated IQ as an additional covariate. 
 
 
 
 
